The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Efficacy of the Long-Acting Repeatable Formulation of the Somatostatin Analogue Octreotide in Postoperative Dumping
Abstract
Background & aims Several studies have established symptomatic and mechanistic benefits of the somatostatin analogue octreotide in patients with dumping syndrome, but clinical use is hampered by the requirement for subcutaneous administration 3 times daily. We compared the efficacy of subcutaneous octreotide with that of the long-acting repeatable (LAR) octreotide formulation, which is administered monthly, in patients with dumping syndrome. Methods The study included 30 consecutive patients with postoperative dumping, evidenced by oral glucose tolerance test (OGTT) results and insufficient response to dietary measures. OGTT, dumping severity score (summary of scores 0-3 for 8 early and 6 late dumping symptoms), and quality-of-life data were evaluated at baseline, after 3 days of subcutaneous administration of octreotide (0.5 mg), and then after 3 monthly intramuscular injections of octreotide LAR (20 mg). Results Both formulations of octreotide significantly reduced total dumping severity scores (21.7 +/- 1.6 at baseline, 11.2 +/- 1.2 for subcutaneous and 14.0 +/- 1.8 for LAR formulations; P Conclusions Monthly administration of LAR octreotide improves OGTT results, symptoms, and quality of life in patients with postoperative dumping.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In severe cases, dumping syndrome is associated with a substantial reduction in quality of life and significant weight loss as a result of avoidance of food intake (15).”
From Dumping syndrome after esophageal, gastric or bariatric surgery: Pathophysiology, diagnosis, and management (2017) · cites this paper as [15]
In the citing paper
“However, gastric emptying studies generally have low sensitivity and specificity, probably because the process of rapid gastric emptying occurs soon after ingestion, a phase that is not adequately assessed in most studies.”
From Dumping syndrome after esophageal, gastric or bariatric surgery: Pathophysiology, diagnosis, and management (2017) · cites this paper as [15]
In the citing paper
“Arts et al. developed a dumping-severity score in which symptoms of early and late dumping (eight and six symptoms, respectively) were scored on a 4-point Likert scale (15).”
From Dumping syndrome after esophageal, gastric or bariatric surgery: Pathophysiology, diagnosis, and management (2017) · cites this paper as [15]
In the citing paper
“Furthermore, the duration of the entire study of up to 4 h is integrated into a single value (half emptying time), which may neutralize the rapid initial emptying effect (3,15,37).”
From Dumping syndrome after esophageal, gastric or bariatric surgery: Pathophysiology, diagnosis, and management (2017) · cites this paper as [15]
In the citing paper
“Short-acting formulations may be more effective at improving some dumping symptoms such as hypoglycemia (15,(81)(82)(83)85); however, the need for repeated injections throughout the day is often a major limitation to the long-term administration of short-acting”
From Dumping syndrome after esophageal, gastric or bariatric surgery: Pathophysiology, diagnosis, and management (2017) · cites this paper as [15]
In the citing paper
“Both short-acting and long-acting formulations of somatostatin analogues have demonstrated efficacy by slowing gastric emptying, improving hypoglycemia and reducing early and late dumping symptoms (Table 4) (15,66,(80)(81)(82)(83)(84)(85)(86)(87)(88)(89)(90)(91)(92)(93)(94)(95).”
From Dumping syndrome after esophageal, gastric or bariatric surgery: Pathophysiology, diagnosis, and management (2017) · cites this paper as [15]
In the citing paper
“Somatostatin analogues target various steps in the pathophysiology of dumping syndrome, including delaying gastric emptying, delaying transit through the small intestine, inhibiting the release of GI hormones, inhibiting insulin secretion and inhibiting postprandial vasodilation (15,(67)(68)(69)(70)(71)(72)(73)(74)(75)(76)(77)(78).”
From Dumping syndrome after esophageal, gastric or bariatric surgery: Pathophysiology, diagnosis, and management (2017) · cites this paper as [15]
In the citing paper
“Long-acting formulations are preferred by patients because of less frequent administration and the associated improvements in quality of life (15,89).”
From Dumping syndrome after esophageal, gastric or bariatric surgery: Pathophysiology, diagnosis, and management (2017) · cites this paper as [15]
Citations
Cites
Esophageal Resection for Cancer of the Esophagus: Long-Term Function and Quality of Life
McLarty, A. J., Deschamps, C., Trastek, V. F., Allen, M. S., Pairolero, P. C., & Harmsen, W. S. (1997) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(97)00125-2 · Cited by 272
Moschetta, A., Stolk, M. F. J., Rehfeld, J. F., Portincasa, P., Slee, P. H. T. J., Koppeschaar, H. P. F., Van Erpecum, K. J., & Vanberge‐Henegouwen, G. P. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.00924.x · Cited by 79
Efficacy of depot long‐acting release octreotide therapy in severe dumping syndrome
PENNING, C., VECHT, J., & MASCLEE, A. A. M. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02681.x · Cited by 48
Effect of octreotide on gastric and small bowel motility in patients with gastroparesis
Edmunds, Chen, Soykan, Lin, & McCallum (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00289.x · Cited by 41
EWINS, D., JAVAID, A., COSKERAN, P., SHAN, S., BUTLER, J., DEPREZ, P., MIELL, J., CALAM, J., BARRETT, J., DAWSON, J., et al. (1992) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068669 · Cited by 25
Research works printed but not linked: 36
- Vecht, 1997, The dumping syndrome, Scand J Gastroenterol, 223, 21
- Pimpalwar, 2002, Results of laparoscopic antireflux procedures in neurologically impaired children, Semin Laparosc Surg, 9, 190, 10.1053/slas.2002.126992 · DOI
- Lawaetz, 1983, Gut hormone profile and gastric emptying in the dumping syndrome, Scand J Gastoenterol, 18, 73, 10.3109/00365528309181562 · DOI
- Sagor, 1981, Release of vasoactive intestinal peptide in the dumping syndrome, Br Med J, 282, 507, 10.1136/bmj.282.6263.507 · DOI
- Kellum, 1990, Gastrointestinal hormone response to meals before and after gastric bypass and vertical banded gastroplasty, Ann Surg, 211, 763, 10.1097/00000658-199006000-00016 · DOI
- Kaushik, 1980, Use of a provocation test for objective assessment of dumping syndrome in patients undergoing surgery for duodenal ulcer, Am J Gastroenterol, 74, 251
- van der Kleij, 1996, Diagnostic value of dumping provocation in patients after gastric surgery, Scand J Gastroenterol, 31, 1162, 10.3109/00365529609036905 · DOI · Paper page
- Linehan, 1986, The 15-minute dumping provocation test, Br J Surg, 73, 810, 10.1002/bjs.1800731017 · DOI
- Hopman, 1988, Treatment of the dumping syndrome with the somatostatin analogue SMS201-995, Ann Surg, 207, 155, 10.1097/00000658-198802000-00007 · DOI · Paper page
- Andersen, 1989, Trial of pectin-enriched muffins in patients with severe dumping syndrome after gastric resection, Acta Chir Scand, 155, 39
- Harju, 1983, Efficacy of guar gum in preventing the dumping syndrome, J Parenter Enteral Nutr, 7, 470, 10.1177/0148607183007005470 · DOI
- Lyons, 1985, Effect of acarbose on biochemical responses and clinical symptoms in dumping syndrome, Digestion, 31, 89, 10.1159/000199185 · DOI
- Vogel, 1988, Clinical and radionuclide evaluation of Roux-Y diversion for postgastrectomy dumping, Ann J Surg, 155, 57, 10.1016/S0002-9610(88)80258-7 · DOI
- Ramus, 1982, The use of jejunal interposition for intractable symptoms complicating peptic ulcer surgery, Br J Surg, 69, 265, 10.1002/bjs.1800690512 · DOI
- Morz, 1982, Influence of somatostatin (SS-14) on early dumping reaction in patients after partial gastrectomy, Z Gastroentrol, 20, 299
- Long, 1985, Somatostatin and the dumping syndrome, Br Med J (Clin Res Ed), 290, 886, 10.1136/bmj.290.6472.886 · DOI
- Reasbeck, 1986, The effect of somatostatin on dumping after gastric surgery: a preliminary report, Surgery, 99, 462
- Tulassay, 1989, Long acting somatostatin analogue in dumping syndrome, Br J Surg, 76, 1294, 10.1002/bjs.1800761223 · DOI · Paper page
- Geer, 1990, Efficacy of octreotide acetate in treatment of severe postgastrectomy dumping syndrome, Ann Surg, 212, 678, 10.1097/00000658-199012000-00005 · DOI
- Li-Ling, 2001, Therapeutic value of octreotide for patients with severe dumping syndrome: a review of randomised controlled trials, Postgrad Med J, 77, 441, 10.1136/pmj.77.909.441 · DOI
- Vecht, 1999, Long-term results of octreotide-therapy in severe dumping syndrome, Clin Endocrinol (Oxf), 51, 619, 10.1046/j.1365-2265.1999.00819.x · DOI
- Fuessl, 1987, Effect of a long-acting somatostatin analogue (SMS 201-995) on postprandial gastric emptying of 99mTc-tin colloid and mouth-to-caecum transit time in man, Digestion, 36, 101, 10.1159/000199407 · DOI · Paper page
- van Berge Henegouwen, 1997, The effect of octreotide on gastric emptying at a dosage used to prevent complications after pancreatic surgery: a randomised, placebo controlled study in volunteers, Gut, 41, 758, 10.1136/gut.41.6.758 · DOI
- Foxx-Orenstein, 2003, Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans, Gut, 52, 1555, 10.1136/gut.52.11.1555 · DOI
- Hasler, 1996, Mechanisms by which octreotide ameliorates symptoms in the dumping syndrome, J Pharmacol Exp Ther, 277, 1359, 10.1016/S0022-3565(25)13083-8 · DOI
- Di Lorenzo, 1999, Effect of sequential erythromycin and octreotide on antroduodenal manometry, J Pediatr Gastroenterol Nutr, 29, 293
- Nelson-Piercy, 1994, Effect of a new oral somatostatin analog (SDZCO611) on gastric emptying, mouth to cecum transit time, and pancreatic and gut hormone release in normal male subjects, J Clin Endocrinol Metab, 78, 329
- von der Ohe, 1995, Differential regional effects of octreotide on human gastrointestinal motor function, Gut, 36, 743, 10.1136/gut.36.5.743 · DOI
- Kreanzlin, 1985, Effect of long-acting somatostatin analogue SMS 201-995 on gut hormone secretion in normal subjects, Experinthia, 41, 738, 10.1007/BF02012573 · DOI
- Williams, 1986, Postprandial effects of SMS 201-995 on gut hormones and glucose tolerance, Scand J Gastroenterol, 21, 73, 10.3109/00365528609087434 · DOI
- Parkinson, 2002, A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal, J Clin Endocrinol Metab, 87, 1797, 10.1210/jcem.87.4.8432 · DOI
- Kemmer, 1992, Inhibition of human exocrine pancreatic secretion by the long-acting somatostatin analogue octreotide (SMS201-995), Aliment Pharmacol Ther, 6, 41, 10.1111/j.1365-2036.1992.tb00543.x · DOI
- Högenauer, 2002, Effect of octreotide on fluid absorption and secretion by the normal human jejunum and ileum in vivo, Aliment Pharmacol Ther, 16, 769, 10.1046/j.1365-2036.2002.01228.x · DOI
- Maton, 1989, Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors, Dig Dis Sci, 34, 28S, 10.1007/BF01536043 · DOI
- Didden, 2006, Octreotide therapy in dumping syndrome: analysis of long-term results, Aliment Pharmacol Ther, 24, 1367, 10.1111/j.1365-2036.2006.03124.x · DOI
- Turner, 1999, Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly, Eur J Endocrinol, 141, 590, 10.1530/eje.0.1410590 · DOI
Cited by
Sorted by citations
Pathophysiology, diagnosis and management of postoperative dumping syndrome
Tack, J., Arts, J., Caenepeel, P., De Wulf, D., & Bisschops, R. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.148 · Cited by 387
Self-citationvan Beek, A. P., Emous, M., Laville, M., & Tack, J. (2017) · Obesity Reviews · doi:10.1111/obr.12467 · Cited by 288
“(15) Single-arm, open-label study N = 30 Octreotide LAR 20 mg for 3 months vs subcutaneous”
BackgroundInfluentialSelf-citationScholtz, S., Miras, A. D., Chhina, N., Prechtl, C. G., Sleeth, M., Daud, N. M., Ismail, N. A., Durighel, G., Ahmed, A. R., Olbers, T., et al. (2013) · Gut · doi:10.1136/gutjnl-2013-305008 · Cited by 293
International consensus on the diagnosis and management of dumping syndrome
Scarpellini, E., Arts, J., Karamanolis, G. P., Laurenius, A., Siquini, W., Suzuki, H., Ukleja, A., van Beek, A. P., Vanuytsel, T., Bor, S., et al. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0357-5 · Cited by 316
“Arts et al.(17) 30 Octreotide longacting release 20 mg (intramuscular) Suppression of rise in pulse rate and haematocrit; inhibition of postprandial hypoglycaemia; inhibition of rise in plasma levels of insulin; improvement of symptoms of early and late dumping syndrome and quality of life; preferred by patients over…”
BackgroundSelf-citationComplications of bariatric surgery: Dumping syndrome, reflux and vitamin deficiencies
Tack, J., & Deloose, E. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.010 · Cited by 181
“In severe cases, dumping syndrome is associated with significant impairment of quality-of-life [3] and may contribute to significant weight loss by avoidance of food intake.”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Arts, J., Caenepeel, P., Bisschops, R., Dewulf, D., Holvoet, L., Piessevaux, H., Bourgeois, S., Sifrim, D., Janssens, J., & Tack, J.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Cliniques Universitaires Saint-Luc (BE)
- Ziekenhuisnetwerk Antwerpen Stuivenberg (BE)
- Corresponding author
- Tack, Jan
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2009-04
- Volume
- 7
- Issue
- 4
- Pages
- 432-437
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2095380880
- Cited by
- 142
- References
- 43
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 15 · 2023: 15 · 2022: 13 · 2021: 9 · 2020: 11 · 2019: 14 · 2018: 8 · 2017: 5 · 2016: 5 · 2015: 8 · 2014: 3 · 2013: 3 · 2012: 4
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Gastroenterology and Hepatology (publishedVersion)
- PubMed (publishedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Bleeding Diagnosis and Treatment
- Keywords
- octreotide, somatostatin analogues, subcutaneous administration, intramuscular injection, oral glucose tolerance test, quality of life, gallstones, postgastrectomy complications
- MeSH terms
- Adult, Belgium, Delayed-Action Preparations, Dumping Syndrome, Female, Gastrointestinal Agents, Glucose Tolerance Test, Humans, Male, Quality of Life, Severity of Illness Index, Octreotide, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
